Uganda: Worm treatment during pregnancy raises moral dilemma
Treating infectious diseases in developing countries might lead to an increase in allergies, according to scientists in Uganda, raising moral issues about the treatment.
A...
Biomed Analysis: Rolling out what works in mobile health
New funding and concrete results are paving the way for scaling up mhealth technologies — but carefully, writes Priya Shetty.
Five years ago, the way that...
Public-private push against neglected diseases unveiled
A major public-private initiative to control or eliminate at least ten neglected tropical diseases (NTDs) by 2020 was unveiled in London yesterday (30 January) alongside a...
Biomed Analysis: Tackling drug-resistant malaria
Emerging resistance to artemisinin means efforts to track genetic markers and regulate the drug's use must step up, says Priya Shetty.
When parasites resistant to the...
Research needed to tackle neglected disease uncertainties
Progress towards tackling neglected tropical diseases (NTDs) will need research to assess uncertainties in how close the scientific community has come to controlling or eradicating them,...
Malaria test success drives up antibiotic use
Antibiotic misuse has soared in an African capital as an unforeseen consequence of improving the diagnosis of malaria, according to a study.
A team testing...
Africa gets ‘holistic’ drug discovery centre
A "holistic" research centre described as the first of its kind in Sub-Saharan Africa to bridge the gap between basic sciences and drug development...
SOUTH AFRICA: Communities debate microbicide results
JOHANNESBURG, 23 August 2010 (PlusNews) - The recent release of positive results from a microbicide trial in South Africa have kick-started discussions...
NGOs call for international regulation of synthetic biology
More than 100 non-governmental organisations (NGOs) have called for greater international oversight of the emerging science of synthetic biology – including a moratorium on...
Janssen Creates new Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA
Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceutica NV, dedicated to bringing the investigational protease inhibitor TMC435 to hepatitis...
